BackgroundSystemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease in which treat-to-target management increasingly emphasizes attainment of Lupus Low Disease Activity State (LLDAS). Complete blood count (CBC)-derived inflammatory indices are inexpensive and readily available markers, but their value for predicting subsequent LLDAS remains unclear.MethodsThis retrospective cohort study included 165 hospitalized patients with SLE at Peking University International Hospital between 2022 and 2024 who had baseline CBC data and completed 1-year follow-up.
Baseline neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI) were calculated from routine hematologic parameters. The primary outcome was LLDAS achievement at 1 year according to Asia Pacific Lupus Collaboration criteria.
Univariable and multivariable logistic regression analyses were performed. Multivariable models adjusted for baseline SLEDAI-2K, age, sex, immunosuppressant use, and prednisone dose.
Frontiers in Immunology published a clinical update in Infectious Disease on 15 Jun 2026.
The item focuses on Baseline neutrophil-to-lymphocyte ratio combined with SLEDAI predicts lupus low disease activity state at 1 year: a cohort study.
Review the original article for the full source wording and details.